<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00634205</url>
  </required_header>
  <id_info>
    <org_study_id>ELCWP-01062</org_study_id>
    <nct_id>NCT00634205</nct_id>
  </id_info>
  <brief_title>Phase II Study of Valproate and Doxorubicin in Malignant Mesothelioma</brief_title>
  <official_title>A Phase II Study Assessing the Activity of Valproate Acid Plus Doxorubicin in Refractory or Recurrent Malignant Mesothelioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Lung Cancer Working Party</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Lung Cancer Working Party</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the response rate to the combination of doxorubicin&#xD;
      and valproate acid in patients with MM failing after at least one previous chemotherapy&#xD;
      regimen including platinum derivatives .&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>Every 3 courses</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>Survival will be dated from the day of registration until death or last follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>After each course of chemotherapy and at the end of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Malignant Mesothelioma</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Continuous oral administration of valproate plus every 3 weeks, intravenous administration of doxorubicin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valproate plus doxorubicin</intervention_name>
    <description>Valproate 20-30 mg/kg orally (in order to obtain serum concentration between 50-100 mcg/ml) Doxorubicin 60 mg/m² intravenously every 3 weeks</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological diagnosis of malignant mesothelioma&#xD;
&#xD;
          -  Unresectable or inoperable malignant mesothelioma failing after at least one prior&#xD;
             chemotherapy regimen including platinum derivatives (cisplatin or carboplatin)&#xD;
&#xD;
          -  At least one evaluable or measurable CT-lesion&#xD;
&#xD;
          -  Availability for participating in the detailed follow-up of the protocol&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are candidates for surgery with curative intent&#xD;
&#xD;
          -  Patient who were previously treated with anthracyclin derivatives&#xD;
&#xD;
          -  Performance status &lt; 60 on the Karnofsky scale&#xD;
&#xD;
          -  A history of prior malignant tumour, except non-melanoma skin cancer or in situ&#xD;
             carcinoma of the cervix and cured malignant tumour (more than 5-year disease free&#xD;
             interval)&#xD;
&#xD;
          -  A history of prior HIV infection&#xD;
&#xD;
          -  Polynuclear cells &lt; 2,000/mm³&#xD;
&#xD;
          -  Platelet cells &lt; 100,000/mm³&#xD;
&#xD;
          -  Abnormal coagulation tests (aPTT, PTT, prothrombin time) and/or decreased fibrinogen&#xD;
&#xD;
          -  Serum bilirubin &gt;1.5 mg/100 ml&#xD;
&#xD;
          -  Transaminases more than twice the normal range&#xD;
&#xD;
          -  Serum creatinine &gt; 1.5 mg/100 ml&#xD;
&#xD;
          -  Recent myocardial infarction (less than 3 months prior to date of diagnosis)&#xD;
&#xD;
          -  Congestive cardiac failure (ejectional fraction of the left ventricle &lt; 50%) or&#xD;
             uncontrolled cardiac arrhythmia&#xD;
&#xD;
          -  Uncontrolled infectious disease&#xD;
&#xD;
          -  Active epilepsy needing a specific treatment&#xD;
&#xD;
          -  Concomitant treatment with IMAO, carbamazepine, mefloquine, phenobarbital, primidone,&#xD;
             phenytoïn, lamotrigine, zidovudine&#xD;
&#xD;
          -  Pregnancy or refusal to use active contraception&#xD;
&#xD;
          -  A known allergy to valproate acid and/or doxorubicin&#xD;
&#xD;
          -  Serious medical or psychological factors which may prevent adherence to the treatment&#xD;
             schedule&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thierry Berghmans, MD</last_name>
    <role>Study Chair</role>
    <affiliation>European Lung Cancer Working Party</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Pneumology CHR St joseph - Warquignies</name>
      <address>
        <city>Boussu</city>
        <zip>7360</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Intensive Care Unit and Thoracic Oncology Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Pneumology Hôpital Ixelles-Molière</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Pneumology CHU Charleroi</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Pneumology Hôpital Saint-Joseph</name>
      <address>
        <city>Gilly</city>
        <zip>6060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Ambroise Paré</name>
      <address>
        <city>Mons</city>
        <zip>7000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Peltzer-La Tourelle</name>
      <address>
        <city>Verviers</city>
        <zip>4800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Pneumology CHRU Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.e-cancer.fr</url>
    <description>Trials registry of the French National Cancer Institute</description>
  </link>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>March 5, 2008</study_first_submitted>
  <study_first_submitted_qc>March 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2008</study_first_posted>
  <last_update_submitted>February 11, 2015</last_update_submitted>
  <last_update_submitted_qc>February 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mesothelioma</keyword>
  <keyword>Valproate</keyword>
  <keyword>Doxorubicin</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Phase II</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Mesothelioma, Malignant</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

